NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
22.09
+0.44 (2.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
NovoCure Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for NovoCure stock have an average target of 33.4, with a low estimate of 17 and a high estimate of 42. The average target predicts an increase of 51.20% from the current stock price of 22.09.
Analyst Consensus: Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for NovoCure stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Hold | 3 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +72.02% | Jan 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $28 → $42 | Buy | Maintains | $28 → $42 | +90.13% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $38 | Strong Buy | Maintains | $30 → $38 | +72.02% | Dec 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 → $38 | Strong Buy | Reiterates | $30 → $38 | +72.02% | Dec 2, 2024 |
| Evercore ISI Group | Evercore ISI Group | Hold → Buy Upgrades $18 → $30 | Hold → Buy | Upgrades | $18 → $30 | +35.81% | Dec 2, 2024 |
Financial Forecast
Revenue This Year
611.04M
from 509.34M
Increased by 19.97%
Revenue Next Year
628.35M
from 611.04M
Increased by 2.83%
EPS This Year
-1.31
from -1.95
EPS Next Year
-1.63
from -1.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 635.6M | 669.9M | 762.1M | |||
| Avg | 611.0M | 628.4M | 692.2M | |||
| Low | 568.4M | 582.1M | 639.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 24.8% | 9.6% | 21.3% | |||
| Avg | 20.0% | 2.8% | 10.2% | |||
| Low | 11.6% | -4.7% | 1.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.25 | -0.97 | -0.93 | |||
| Avg | -1.31 | -1.63 | -1.61 | |||
| Low | -1.36 | -1.97 | -2.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.